Gilead Sciences Stock-Based Comp remained flat by 0.0% to $230.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 3.6%, from $222.00M to $230.00M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 8.9% CAGR.
An increase may signal a strategy to preserve cash or align employee interests with shareholders, but it also results in share dilution.
Stock-based compensation is a non-cash expense where employees and executives are rewarded with equity or stock options...
High-growth technology firms often have higher stock-based compensation as a percentage of revenue compared to mature industrial firms.
cf_stock_based_compensation| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $166.00M | $171.00M | $159.00M | $130.00M | $165.00M | $168.00M | $174.00M | $165.00M | $198.00M | $202.00M | $201.00M | $187.00M | $210.00M | $216.00M | $222.00M | $209.00M | $225.00M | $230.00M | $230.00M |
| QoQ Change | — | +3.0% | -7.0% | -18.2% | +26.9% | +1.8% | +3.6% | -5.2% | +20.0% | +2.0% | -0.5% | -7.0% | +12.3% | +2.9% | +2.8% | -5.9% | +7.7% | +2.2% | +0.0% |
| YoY Change | — | — | — | — | -0.6% | -1.8% | +9.4% | +26.9% | +20.0% | +20.2% | +15.5% | +13.3% | +6.1% | +6.9% | +10.4% | +11.8% | +7.1% | +6.5% | +3.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.